In聽vivo performance of a drug-eluting contact lens to treat glaucoma for a month

详细信息    查看全文

• 作者：Joseph B. Ciolino ; Cristina F. Stefanescu ; Amy E. Ross ; Borja Salvador-Culla ; Priscila Cortez ; Eden M. Ford ; Kate A. Wymbs ; Sarah L. Sprague ; Daniel R. Mascoop ; Shireen S. Rudina ; Sunia A. Trauger ; Fabiano Cade ; Daniel S. Kohane
• 关键词：Drug delivery ; Contact lens ; Sustained release ; Latanoprost ; Glaucoma ; Ocular release
• 刊名：Biomaterials
• 出版年：January, 2014
• 年：2014
• 卷：35
• 期：1
• 页码：432-439
• 全文大小：1714 K

文摘

For nearly half a century, contact lenses have been proposed as a means of ocular drug delivery, but achieving controlled drug release has been a significant challenge. We have developed a drug-eluting contact lens designed for prolonged delivery of latanoprost for the treatment of glaucoma, the leading cause of irreversible blindness worldwide. Latanoprost-eluting contact lenses were created by encapsulating latanoprost-poly(lactic-co-glycolic acid) films in methafilcon by ultraviolet light polymerization. In聽vitro and in聽vivo studies showed an early burst of drug release followed by sustained release for one month. Contact lenses containing thicker drug-polymer films demonstrated released a greater amount of drug after the initial burst. In聽vivo, single contact lenses were able to achieve, for at least one month, latanoprost concentrations in the aqueous humor that were comparable to those achieved with topical latanoprost solution, the current first-line treatment for glaucoma. The lenses appeared safe in cell culture and animal studies. This contact lens design can potentially be used as a treatment for glaucoma and as a platform for other ocular drug delivery applications.